N/A
N=1,464
Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool
Opioid Abuse · Prescription Drug Abuse (Not Dependent)
Bottom Line
View on ClinicalTrials.gov: NCT03936985 ↗Enrolled (actual)
1,464
Serious AEs
—
Results posted
Jul 2024
Primary outcome: Primary: Validity of the PDMP Narcotic Score Versus the WHO ASSIST — .70; .74 probability
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Utah
- Primary completion
- Aug 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Validity of the PDMP Narcotic Score Versus the WHO ASSIST |
.70; .74 | — |
Summary
The goal of the study is to validate a Prescription Drug Monitoring Program-based opioid risk metric to discriminate between low, moderate, and high-risk opioid use disorder. The World Health Organization Alcohol, Smoking, and Substance Involvement Screening Test (WHO ASSIST) will be used as the gold standard instrument that defines patient risk levels. No intervention or hypothesis will be tested.
Eligibility Criteria
Inclusion Criteria
- be dispensed ≥1 opioid medication (including tramadol) by a participating pharmacy;
- be ≥18 years of age according to pharmacy data and self-report
Exclusion Criteria
- solely filling buprenorphine or buprenorphine combination products i.e., patients receiving OUD treatment with no other opioid medication use;
- currently receiving treatment for cancer;
- having previously completed the survey;
- having current involvement with the criminal justice system that has, or could, lead to incarceration
Data sourced from ClinicalTrials.gov (NCT03936985). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.